Why the ASC Boom in 2026 Is the Biggest Opportunity in Medical Device Sales Right Now

If there is one development in the 2026 healthcare landscape that medical device sales professionals and manufacturers need to fully understand, it is the accelerating shift of high-acuity procedures into ambulatory surgery centers. This is not a slow trend that will play out over the next decade. It is happening right now, and the commercial window it is opening is significant.

In late 2025, the Centers for Medicare and Medicaid Services finalized its 2026 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System rule, which added more than 500 procedures to the ASC Covered Procedures List. Included in that expansion are AFib-treating cardiac catheter ablation and a range of high-acuity cardiology and spine procedures that were previously confined to hospital inpatient settings.

For context: these are not minor procedures migrating to a lower-acuity setting. These are complex, technology-dependent cases that require sophisticated device support, and they are now cleared to happen in freestanding ASCs.

Why This Matters for Device Sales

The medical device purchasing dynamics in an ASC are fundamentally different from those in a hospital system. ASCs are typically leaner organizations with more direct decision-making, fewer bureaucratic layers, and physician owners who are often personally involved in purchasing decisions.

This means the sales cycle can move faster, the relationship between the device rep and the decision-maker is more direct, and the clinical champion is frequently the same person who controls the budget. For experienced device sales professionals who understand how to work these accounts, the ASC environment can be significantly more productive per call than large health system selling.

At the same time, ASCs are new to many of the procedure categories that are now entering their setting. They need clinical support, device training, and vendor relationships they can rely on as they build competency in higher-acuity work. The device organizations that establish themselves as trusted partners in these ASCs now will hold a durable competitive advantage.

The Scale of the Opportunity

The shift to outpatient and ambulatory care is not limited to the 2026 CMS rule. Industry forecasts from EY and others project that ambulatory and post-acute services will drive the majority of healthcare volume growth over the next decade, outpacing both inpatient and emergency settings significantly.

For manufacturers and distribution organizations, this means the center of gravity in healthcare purchasing is shifting. The ASC market, which was historically lower acuity and lower complexity, is becoming a significant purchaser of the kinds of specialty devices that used to flow almost exclusively through hospital buying groups and integrated delivery networks.

How to Approach ASC Accounts in 2026

ASC administrators and physician owners respond well to direct, efficient communication. Unlike hospital committee processes that can span months, ASC decisions often move faster when the right clinical and financial case is made.

Understanding the physician ownership structure of the ASC you are targeting matters. Physician-owned ASCs make purchasing decisions with a direct line-of-sight to both clinical outcomes and financial returns. Demonstrating how your product improves procedure efficiency, reduces complication rates, or supports the kinds of high-acuity cases they are newly cleared to perform is the most powerful sales argument you can make.

Knowing the specific procedure mix of the ASC, and which of the newly CMS-approved procedures they are planning to add, allows you to position your product as a solution to a need they are actively working to address.

DAVAB Health Systems and the ASC Market

At DAVAB Health Systems, we have been closely tracking the CMS rule changes and the ASC procedure expansion, and we are actively positioning our manufacturer partners to capitalize on this market shift. Our team understands how to navigate ASC purchasing, develop physician-owner relationships, and support the clinical onboarding that new procedure categories require.

If you are a manufacturer whose products are relevant to any of the procedure categories moving into the ASC setting, or a sales professional looking to build expertise in this rapidly growing market, we want to talk. Email us at sales@davabhealth.com to start the conversation.